Exhibit 99.1
Exhibit
99.1
Medovex Corporation Announces
First Human Cases
Using Its DenerveX Device and
First Revenue Events
Highly Disruptive and
Patented Less Invasive Device with Faster Recovery
Time than Current Surgical
Treatment Options for Facet Joint Syndrome
ATLANTA,
GA--(Marketwired – July 19, 2017) - Medovex Corp. (NASDAQ:
MDVX), (“Medovex”
or the “Company”), a developer of medical technology
products, today announced the first human cases performed using its
recently launched DenerveX™ System and first revenue
events.
The DenerveX System which has recently received
CE Mark approval and clearance for commercialization in the
European countries, is a new and novel
device designed for enduring relief of Facet Joint Syndrome
related to lower back pain.
Jarrett
Gorlin, Medovex CEO stated, “Our first human use cases for
the DenerveX System which took place in Manchester, England
recently with very encouraging initial procedural success. We
anticipate performing up to as many as 30 plus additional
procedures by the end of August. This is the beginning of
delivering on our goal of “proof of principle” in the
adoption of the technology in this very sizable market.”
Gorlin concluded, “We are also pleased to have also reached
our first revenue events in the EU with others soon to expected to
follow.”
The DenerveX
System offers a fast and simple way to perform a safe Facet Joint
Syndrome treatment.
Patrick Kullmann, Medovex President
and COO., added, "With the DenerveX™ System, we can offer
surgeons and pain management specialists the ability to attain
precise treatment of the Facet Joint pain. The DenerveX
treatment uses “Rotacapsulation™, a combination of high
heat and rotational capsular tissue shaving, in a minimally
invasive posterior procedure for the treatment of Facet Joint
Syndrome. The DenerveX System offers an alternative to existing
treatments only providing temporary
relief.”
Facet Joint Syndrome (FJS), also
known as spinal osteoarthritis, spinal arthritis, or facet joint
osteoarthritis, is a significant health and economic problem in the
United States and other countries in the EU and Rest of World
affecting millions each year. Current treatment options are generally
temporary and there is no proven long-lasting option for
FJS.
The DenerveX System is a highly
differentiated technology. It denervates and removes
capsular tissue from the Facet Joint in one single procedure.
Treatment results from the combined effect of a deburring or
polishing action and RF ablation treatment on the Facet Joint.
Using this new technique, the slowly rotating burr removes the
targeted facet joint synovial membrane and joint surface while
the heat ablation destroys tissue and denudes any residual
nervous and synovial membrane overlying the joint, removing
the end point sensory tissue of the joint.
The DenerveX System consists of the
DenerveX Kit which contains the DenerveX Device, a single use
medical device and the DenerveX Pro-40 Power Generator. DenerveX
system is not yet FDA cleared.
About
Medovex
Medovex
was formed to acquire and develop a diversified portfolio of
potentially ground breaking medical technology products. Criteria
for selection include those products with potential for significant
improvement in the quality of patient care combined with cost
effectiveness. The Company's first pipeline product, the DenerveX
device, is intended to provide long lasting relief from pain
associated with facet joint syndrome at significantly less cost
than currently available options. To learn more about Medovex
Corp., visit www.medovex.com
Safe
Harbor Statement
Certain
statements in this press release constitute "forward-looking
statements" within the meaning of the federal securities laws.
Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "predict,"
"forecast," "project," "plan," "intend" or similar expressions, or
statements regarding intent, belief, or current expectations, are
forward-looking statements. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC"),
not limited to Risk Factors relating to its patent business
contained therein. Thus, actual results could be materially
different. The Company expressly disclaims any obligation to update
or alter statements whether as a result of new information, future
events or otherwise, except as required by law.
CONTACT
INFORMATION